Nuscale Power Corporation vs Twist Bioscience Corp — how do they compare? Nuscale Power Corporation trades at $7.2 (market cap $3.00B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 3.4× Nuscale Power Corporation's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 29 Days and Twist Bioscience Corp for 27 Days on average.
| SMR | TWST | |
|---|---|---|
Market Cap | $3.00B | $10.08B |
Volume | 43,143,109 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $53.43 | $205.00 |
52-Week Low | $7.20 | $25.45 |
Typical Hold Time | 29 Days | 27 Days |
Enterprise Value | $1.93B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
NuScale Power (SMR) trades at $7.32, down 4.56% with bearish technical signals. The company shows concerning fundamentals with negative net income margin of -3,888.7% and declining revenue from $31.48M in 2025 to $11M in 2026. Despite operating cash burn, financing activities provided $1.31B in 2025. Analyst consensus is mixed with 50% buy ratings but ongoing SEC investigation concerns.
The stock faces significant execution risk in commercializing SMR technology amid cash burn and competitive pressure. Upside exists if NuScale achieves commercialization milestones, with analyst targets up to $16. However, current financial performance and negative margins present substantial risk for investors seeking near-term returns.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →